查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球湿性老龄化黄斑部病变(Wet AMD) 市场：按治疗类型和地区分析和预测（2025-2035 年）
市场调查报告书
商品编码
1734251

全球湿性老龄化黄斑部病变(Wet AMD) 市场：按治疗类型和地区分析和预测（2025-2035 年）

Wet Age-Related Macular Degeneration (Wet AMD) Market - A Global and Regional Analysis: Focus on Treatment Type, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

由于老年人口的增加、人们对该疾病的认识的提高以及治疗方法的进步，全球湿性老龄化黄斑部病变市场正在经历强劲增长。

湿性老龄化黄斑部病变病变的主要治疗方法包括抗VEGF（血管内皮生长因子）疗法、动态疗法（PDT）和雷射手术，其中抗VEGF药物因其在预防或减缓疾病进展方面的有效性而占据最大的市场占有率份额。

该市场最重要的成长要素是全球人口老化。随着人们寿命的延长，包括老龄化老龄化黄斑部病变部病变在内的老年性眼科疾病的发生率也在增加。老龄化黄斑部病变在65岁及以上人口中特别常见，随着老龄人口的增加，尤其是已开发国家，湿性老龄化黄斑部病变患者的数量也在增加。联合国预测，80岁及以上人口将从2019年的1.43亿增加到2050年的4.26亿，预计将增加需要治疗黄斑部病变的患者人数。

光同调断层扫瞄(OCT) 和眼底照相等技术的进步大大提高了我们早期检测湿性老龄化黄斑部病变的能力。早期诊断的能力可以及时干预，以减缓疾病进展并改善患者的预后。诊所和医院越来越多地采用这些先进的诊断设备，可以帮助识别需要抗 VEGF 治疗和其他治疗的患者，从而推动市场成长。

随着湿性老龄化市场不断发展，长效治疗方法的开发、采用人工智慧早期检测等先进诊断技术以及对个人化医疗日益增长的兴趣黄斑部病变新趋势预计将决定未来的市场方向。对更实惠、更有效、更容易获得的治疗方法的需求不断增长，特别是在医疗基础设施不发达的地区，预计将为市场扩张创造巨大的机会。

本报告调查了全球湿性老龄化性黄斑部病变市场，并总结了主要趋势、影响市场的因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章 全球湿性老龄化黄斑部病变市场：产业展望

  • 市场趋势
  • 法律规范
  • 流行病学
  • 临床试验分析
  • 市场动态
    • 影响分析
    • 市场驱动因素
    • 市场挑战
    • 市场机会

第二章 全球湿性老龄化黄斑部病变市场（依治疗类型划分）

  • 抗VEGF治疗
  • 基因治疗
  • 其他的

3. 全球湿性老龄化黄斑部病变市场（按地区）

  • 北美洲
  • 欧洲
  • 亚太地区
    • 主要发现
    • 市场动态
    • 市场规模及预测

第四章全球湿性老龄化黄斑部病变市场：竞争格局与公司概况

  • 各公司主要策略及发展
    • 资金筹措活动
    • M&A
    • 监管部门核准
    • 伙伴关係、合作和业务扩展
  • 公司简介
    • Regeneron Pharmaceuticals Inc
    • Ophthotech Corporation
    • Adverum Biotechnologies Inc
    • Apellis Pharmeceuticals Inc
    • Kubota Pharmaceutical Holdings Co. Ltd.
    • Pfizer Inc.
    • Novartis AG

第五章调查方法

Product Code: BHL2882SA

Global Wet Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035

Wet age-related macular degeneration is a progressive eye disease that is a leading cause of vision loss in individuals over the age of 50. It occurs when abnormal blood vessels grow under the retina, leaking fluid and causing damage to the macula, which is responsible for central vision. The condition severely affects the ability to read, recognize faces, and perform other tasks that require sharp vision. Wet age-related macular degeneration represents a major challenge for healthcare systems globally, as it significantly impacts the quality of life and imposes a high burden on individuals and economies.

The global wet age-related macular degeneration market is experiencing robust growth, driven by an aging population, increasing awareness about the condition, and advancements in treatment options. Key therapeutic approaches for wet age-related macular degeneration include anti-VEGF (vascular endothelial growth factor) therapies, photodynamic therapy, and laser surgeries, with the anti-VEGF drugs holding the largest market share due to their proven efficacy in halting or slowing disease progression. Furthermore, emerging treatments, including cell and gene therapy and stem cell therapy, are gaining attention as potential future solutions.

The most significant driver for the wet age-related macular degeneration market is the aging global population. As people live longer, the incidence of age-related eye conditions, including wet age-related macular degeneration, increases. Age-related macular degeneration is most common in individuals aged 65 and older, and as the world's elderly population continues to grow, particularly in developed nations, the number of wet age-related macular degeneration cases rises. The UN projects that the number of people aged 80 and older will increase from 143 million in 2019 to 426 million by 2050, leading to a larger patient pool for wet age-related macular degeneration treatments.

Technologies such as optical coherence tomography (OCT) and fundus photography have greatly enhanced the ability to detect wet age-related macular degeneration at an early stage. Early diagnosis allows for timely intervention, helping to slow disease progression and improve patient outcomes. The adoption of advanced diagnostic tools in clinics and hospitals is driving market growth by enabling healthcare providers to identify patients who would benefit from anti-VEGF therapies or other treatments.

The wet age-related macular degeneration market is indeed growing due to increasing awareness, technological advances in treatments, and an aging global population. However, the combination of high treatment costs, side effects, limited access to care, and the ongoing challenge of offering curative treatments are significant factors restricting the market's potential. Companies in the sector need to focus on reducing the cost of treatment, improving patient adherence, and advancing research to provide long-term and potentially curative therapies for Wet AMD. Addressing these challenges will be key to unlocking the market's full growth potential.

Some of the major players in the global wet age-related macular degeneration market, such as Regeneron Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, and Adverum Biotechnologies Inc., are continuously innovating to improve the effectiveness and comfort of wet age-related macular degeneration products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of wet age-related macular degeneration while enhancing their market positions globally.

The competitive landscape of the global wet age-related macular degeneration market is diverse, with numerous players across different regions offering a wide range of products. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the wet age-related macular degeneration market will continue to evolve, fostering new opportunities for both established and emerging companies.

Market Segmentation:

Segmentation 1: by Treatment Type

  • Anti-VEGF Therapies
  • Gene Therapy
  • Others

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific

As the wet age-related macular degeneration market continues to evolve, emerging trends such as the development of long-acting therapies, the integration of advanced diagnostic technologies like artificial intelligence (AI) for early detection, and the increasing focus on personalized medicine will shape its future trajectory. The growing demand for more affordable, effective, and accessible wet age-related macular degeneration treatments, particularly in underserved regions with limited healthcare infrastructure, will create significant opportunities for market expansion.

In conclusion, the global wet age-related macular degeneration market is on track for continued growth, driven by the aging population, increasing awareness of wet age-related macular degeneration, and the development of more effective and comfortable solutions. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for wet age-related macular degeneration solutions rises, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems alike, improving the quality of life for people living with incontinence.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Wet Age-Related Macular Degeneration Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology of Wet Age-Related Macular Degeneration
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Wet Age-Related Macular Degeneration Market, by Treatment Type, $Million, 2023-2035

  • 2.1 Anti-VEGF Therapies
  • 2.2 Gene Therapy
  • 2.3 Others

3. Global Wet Age-Related Macular Degeneration Market, by Region, $Million, 2023-2035

  • 3.1 North America
    • 3.1.1 Key Findings
    • 3.1.2 Market Dynamics
    • 3.1.3 Market Sizing and Forecast
      • 3.1.3.1 North America Wet Age-Related Macular Degeneration Market, by Country
        • 3.1.3.1.1 U.S.
  • 3.2 Europe
    • 3.2.1 Key Findings
    • 3.2.2 Market Dynamics
    • 3.2.3 Market Sizing and Forecast
      • 3.2.3.1 Europe Wet Age-Related Macular Degeneration Market, by Country
        • 3.2.3.1.1 Germany
        • 3.2.3.1.2 U.K.
        • 3.2.3.1.3 France
        • 3.2.3.1.4 Italy
        • 3.2.3.1.5 Spain
  • 3.3 Asia Pacific
    • 3.3.1 Key Findings
    • 3.3.2 Market Dynamics
    • 3.3.3 Market Sizing and Forecast
      • 3.3.3.1 Asia Pacific Wet Age-Related Macular Degeneration Market, by Country
        • 3.3.3.1.1 Japan

4. Global Wet Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles

  • 4.1 Key Strategies and Developments by Company
    • 4.1.1 Funding Activities
    • 4.1.2 Mergers and Acquisitions
    • 4.1.3 Regulatory Approvals
    • 4.1.4 Partnerships, Collaborations and Business Expansions
  • 4.2 Company Profiles
    • 4.2.1 Regeneron Pharmaceuticals Inc
      • 4.2.1.1 Overview
      • 4.2.1.2 Top Products / Product Portfolio
      • 4.2.1.3 Target Customers/End-Users
      • 4.2.1.4 Key Personnel
      • 4.2.1.5 Analyst View
    • 4.2.2 Ophthotech Corporation
      • 4.2.2.1 Overview
      • 4.2.2.2 Top Products / Product Portfolio
      • 4.2.2.3 Target Customers/End-Users
      • 4.2.2.4 Key Personnel
      • 4.2.2.5 Analyst View
    • 4.2.3 Adverum Biotechnologies Inc
      • 4.2.3.1 Overview
      • 4.2.3.2 Top Products / Product Portfolio
      • 4.2.3.3 Target Customers/End-Users
      • 4.2.3.4 Key Personnel
      • 4.2.3.5 Analyst View
    • 4.2.4 Apellis Pharmeceuticals Inc
      • 4.2.4.1 Overview
      • 4.2.4.2 Top Products / Product Portfolio
      • 4.2.4.3 Target Customers/End-Users
      • 4.2.4.4 Key Personnel
      • 4.2.4.5 Analyst View
    • 4.2.5 Kubota Pharmaceutical Holdings Co. Ltd.
      • 4.2.5.1 Overview
      • 4.2.5.2 Top Products / Product Portfolio
      • 4.2.5.3 Target Customers/End-Users
      • 4.2.5.4 Key Personnel
      • 4.2.5.5 Analyst View
    • 4.2.6 Pfizer Inc.
      • 4.2.6.1 Overview
      • 4.2.6.2 Top Products / Product Portfolio
      • 4.2.6.3 Target Customers/End-Users
      • 4.2.6.4 Key Personnel
      • 4.2.6.5 Analyst View
    • 4.2.7 Novartis AG
      • 4.2.7.1 Overview
      • 4.2.7.2 Top Products / Product Portfolio
      • 4.2.7.3 Target Customers/End-Users
      • 4.2.7.4 Key Personnel
      • 4.2.7.5 Analyst View

5. Research Methodology

List of Figures

  • Figure: Global Wet Age-Related Macular Degeneration Market, Dynamics Impact Analysis
  • Figure: Epidemiology of Wet Age-Related Macular Degeneration
  • Figure: Global Wet Age-Related Macular Degeneration Market Coverage
  • Figure: Global Wet Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Wet Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables

  • Table: Global Wet Age-Related Macular Degeneration Market, Clinical Trial Analysis,
  • Table: Global Wet Age-Related Macular Degeneration Market Dynamics, Impact Analysis
  • Table: Global Wet Age-Related Macular Degeneration Market (by Treatmet Type), $Million, 2023-2035
  • Table: Global Wet Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035